Peptide Initiative

Peptide profile · Cosmetic

Palmitoyl Tripeptide-1

Collagen-stimulating matrikine peptide and key component of Matrixyl 3000 for comprehensive anti-aging skin renewal.

Limited human trialsResearch compound
Limited data; peptide is susceptible to enzymatic degradation in skin but palmitoylation improves stability compared to unmodified GHKHalf-life
Enhanced topical penetration via palmitoyl lipid modification; reaches dermis where fibroblasts resideBioavailability
578.8Molecular weight, Da

Molecular formula

C30H54N6O5

CAS number
147732-56-7
PubChem
10231864
Developed · 2002
Lipotec S.A. research team, Lipotec S.A. (Lubrizol Corporation)

Amino acid sequence

Pal-Gly-His-Lys (palmitoylated GHK tripeptide)

Collagen ProductionDirectly activates TGF-β pathway in dermal fibroblasts to stimulate synthesis of collagen types I, III, IV, and VII along with other ECM proteins.

9.0

Anti-AgingClinical studies demonstrate up to 55% collagen density increase and 19% elasticity improvement over 12 weeks of consistent application.

8.5

Skin FirmnessComprehensive ECM remodeling including elastin, glycosaminoglycans, and decorin production restores structural integrity to aging skin.

8.3

Ratings out of 10.

0.002 % – 10 ppm

Every documented dose level

PhaseDoseFrequency
OngoingUnder 10 ppm (<0.001%) in finished productOnce or twice daily
OngoingUp to ~0.002% in finished productOnce or twice daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for individuals seeking comprehensive collagen stimulation through topical skincare & those with aging skin showing loss of firmness, elasticity, and density

Best for

  • Individuals seeking comprehensive collagen stimulation through topical skincare

    Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on individuals seeking comprehensive collagen stimulation through topical skincare. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Those with aging skin showing loss of firmness, elasticity, and density

    Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on those with aging skin showing loss of firmness, elasticity, and density. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • People looking for non-invasive alternatives to injectable collagen treatments

    Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on people looking for non-invasive alternatives to injectable collagen treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Those seeking GHK-based skin benefits without copper peptide formulation complexity

    Palmitoyl Tripeptide-1 is particularly well-suited for individuals focused on those seeking ghk-based skin benefits without copper peptide formulation complexity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for cosmetic supportConsult your healthcare provider for alternatives to Palmitoyl Tripeptide-1 based on your specific needs and medical history
Alternative cosmetic peptidesGHK-Cu (Copper Peptide)Argireline (Acetyl Hexapeptide-3)Matrixyl (Palmitoyl Pentapeptide-4)
Non-peptide cosmetic approachesRetinol/RetinoidsHyaluronic acid serumsVitamin C serums

Do not use if

  • Known hypersensitivity to palmitoyl tripeptide-1 or related peptide ingredients
  • Active skin infections or severely compromised skin barrier at application site
  • Open wounds or actively inflamed dermatitis in treatment area
  • No known systemic contraindications for topical cosmetic use

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Palmitoyl Tripeptide-1 use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Palmitoyl Tripeptide-1 with similar peptides to find the best fit for your goals.

Route

Palmitoyl Tripeptide-1 is administered Topical—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Palmitoyl Tripeptide-1 dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Palmitoyl tripeptide-1 demonstrates excellent cosmetic safety with GRAS/safe-for-use designation in topical formulations at concentrations up to 2%.

No serious adverse events in 20+ years of cosmetic industry use; mild erythema (<1% of subjects) at high concentrations (>5%). Dermal penetration limited to stratum corneum; no systemic absorption in vitro. Compatible with common skincare ingredients.

Cosmetic safety testing database and published dermatology literature confirm collagen synthesis enhancement through procollagen α1(I) gene expression increases (quantitative real-time PCR).

Skin firmness improvements of 20-30% measured through elastometry and mechanical testing over 8-12 weeks application. Dermatological safety per Cosmetic Ingredient Review confirms safety with no irritation at concentrations up to 2%.


Common side effects · experienced by some users

Temporary Skin Irritation

Mild tingling or warmth upon initial application in sensitive individuals. Self-resolving within minutes.

Management
Perform patch test before full-face application. Reduce to once daily if irritation occurs.

Mild Redness

Transient redness at the application site, particularly when combined with other active ingredients.

Management
Simplify skincare routine. Space application of peptides and other actives.

Dryness

Occasional mild dryness when used concurrently with retinoids or strong exfoliants.

Management
Apply hydrating moisturizer over peptide serum. Alternate active ingredients on different days.

Mild Peeling

Minor skin flaking when combined with high-strength chemical exfoliants.

Management
Reduce exfoliant frequency. Ensure adequate moisturization.

Serious side effects

Skin Sensitization from Fragmented Peptide

The short tripeptide length could theoretically be more rapidly degraded or generate allergenic fragments during topical application, potentially causing delayed type hypersensitivity reactions with repeated exposure.

Management
Patch test for 48 hours before use; discontinue if sensitization develops; avoid use in individuals with sensitive skin or peptide allergies; use in non-sensitizing formulations.

Less commonContact Dermatitis

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Palmitoyl Tripeptide-1
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Palmitoyl Tripeptide-1 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafePalmitoyl Tetrapeptide-7 — May be used together under medical guidance.
  • SafeHyaluronic Acid — May be used together under medical guidance.
  • SafeVitamin C — May be used together under medical guidance.

With medications

  • CautionHigh-Concentration AHAs/BHAs — Use with caution—discuss with your healthcare provider.
  • CautionBenzoyl Peroxide — Use with caution—discuss with your healthcare provider.
  • CautionVery Alkaline Products (pH >8) — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Palmitoyl Tripeptide-1. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs weeks 1-4

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Palmitoyl-tripeptide-1 is the shortest lipidated signal peptide that stimulates collagen and elastin production in your skin.

The fatty acid attachment helps it penetrate deep into skin layers, where it activates fibroblasts to rebuild the skin's structural support system. This results in firmer, more elastic, and more youthful-appearing skin.

The deeper mechanism

Palmitoyl-tripeptide-1 is a three-amino acid peptide conjugated to palmitic acid that serves as a signal peptide for fibroblast-mediated collagen synthesis.

The palmitic acid moiety increases skin barrier penetration through lipid partitioning into the stratum corneum, allowing the tripeptide to reach viable epidermis and dermis.

The tripeptide sequence activates fibroblast receptors (potentially growth factor receptors or G-protein coupled receptors) that increase type I collagen gene expression through MAPK/ERK and PI3K/Akt pathway activation.

Compared to longer palmitoyl-peptides, the tripeptide has reduced specificity but may avoid potential off-target effects. Palmit-oyl-tripeptide-1 improves skin thickness, elasticity, and hydration through enhanced ECM production.


What to expect

  1. Weeks 1-4

    What you might notice

    • Cellular-level activation begins
    • Fibroblasts respond to TGF-β signaling with increased ECM protein gene expression
    • Early improvements in skin texture and hydration may be noticed

    What's normal

    • Full integration of Palmitoyl Tripeptide-1 into physiological systems is established
    • Long-term Palmitoyl Tripeptide-1 response remains personalized to your physiology
    • Palmitoyl Tripeptide-1 tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established Palmitoyl Tripeptide-1 protocol for sustained benefits
    • Continue periodic monitoring to confirm Palmitoyl Tripeptide-1 efficacy
    • Review comprehensive Palmitoyl Tripeptide-1 response with your provider
  2. Weeks 4-12

    What you might notice

    • Collagen and elastin synthesis accelerates
    • Measurable improvements in skin firmness, elasticity, and fine line depth
    • Clinical studies show significant collagen density increases during this period

    What's normal

    • Palmitoyl Tripeptide-1 is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Palmitoyl Tripeptide-1's mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Palmitoyl Tripeptide-1 dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Weeks 12-24+

    What you might notice

    • Near-maximal collagen density improvement (up to 55% increase)
    • Sustained improvements in skin elasticity (up to 19%), hydration (up to 28%), and wrinkle reduction
    • Continued use maintains benefits

    What's normal

    • Full therapeutic effects of Palmitoyl Tripeptide-1 are well-characterized at this point
    • Maintenance of Palmitoyl Tripeptide-1's therapeutic effects is typical
    • Tolerance patterns with Palmitoyl Tripeptide-1 are generally stable over months

    What's next

    • Comprehensive assessment of Palmitoyl Tripeptide-1 efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Palmitoyl Tripeptide-1 over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is the difference between Palmitoyl Tripeptide-1 and GHK-Cu?

Both are based on the same GHK tripeptide sequence. GHK-Cu chelates a copper ion for additional antioxidant and wound-healing properties but requires careful formulation due to copper reactivity. Palmitoyl Tripeptide-1 replaces the copper with a palmitic acid chain, improving skin penetration and formulation stability while maintaining collagen-stimulating activity. They share similar ECM-stimulating mechanisms but differ in delivery and secondary effects.

Why is Palmitoyl Tripeptide-1 combined with Palmitoyl Tetrapeptide-7 in Matrixyl 3000?

The two peptides have complementary mechanisms. Palmitoyl Tripeptide-1 stimulates collagen synthesis through TGF-β activation, while Palmitoyl Tetrapeptide-7 reduces inflammation by inhibiting IL-6 secretion. Together they address both the constructive (building new collagen) and protective (reducing inflammatory degradation) aspects of skin aging simultaneously.

How does Palmitoyl Tripeptide-1 compare to Palmitoyl Pentapeptide-4 (Matrixyl)?

Both stimulate collagen production in fibroblasts, but through slightly different signaling cascades. Palmitoyl Pentapeptide-4 (KTTKS) is a type I procollagen fragment, while Palmitoyl Tripeptide-1 (GHK) is a naturally occurring peptide with broader biological effects including stemness restoration. Palmitoyl Tripeptide-1 stimulates more collagen types (I, III, IV, and VII) and has additional effects on integrin signaling.

Is Palmitoyl Tripeptide-1 safe for sensitive skin?

Yes. Palmitoyl Tripeptide-1 has been assessed as safe for cosmetic use by the CIR (Cosmetic Ingredient Review) panel. It is generally well-tolerated across all skin types, including sensitive skin. A patch test is recommended for individuals with a history of topical allergies.

Can Palmitoyl Tripeptide-1 be used with retinol?

Yes, the two ingredients work through complementary mechanisms and can be used together. However, both can cause mild irritation in sensitive individuals. Consider applying them at different times of day (peptides in the morning, retinol in the evening) or on alternating days if sensitivity occurs.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Palmitoyl Tripeptide-1, on one page.

Palmitoyl Tripeptide-1 dosing protocol

Medical disclaimer

Palmitoyl Tripeptide-1 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

0.002 % – 10 ppm Once or twice daily · onset 1-2 weeks
Open the Palmitoyl Tripeptide-1 calculatorPalmitoyl Tripeptide-1 calculator